AbbVie's study also met all secondary goals, with 64.1% patients on Qulipta seeing a 50% or more reduction in the average ...

Early intervention in high-risk smoldering myeloma with lenalidomide delays progression by up to 7 years and achieves ...

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

The Patented Medicine Prices Review Board (PMPRB) published the 9th edition of its annual Meds Entry Watch report today. Like last year, the analysis finds that the number of new medicines launched in ...

GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...

EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, underscoring the urgent need for new treatment options The multiple regulatory ...

FDA recommends inclusion of patients as young as 6 months - younger than Moleculin had proposed - to be allowed in the ...

A comprehensive analysis conducted by public health experts at Novartis Romania reveals that Romanian patients may wait, on ...

Introduction Over the past few years, the European Union has been actively working to overhaul its pharmaceutical legislative framework to better address unmet medical needs, such as those ...

Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the debut of a powerful new ...

to the European Medicines Agency (EMA) for glepaglutide, a long-acting GLP-2 analog, for the treatment of adult patients with short bowel syndrome (SBS). The submission of the MAA to the EMA ...